Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2018 banner

Since ESMO 2016, the ESMO Patient Advocacy Track has been fully integrated in the Congress programme, enabling patient advocates to attend the scientific sessions that are relevant to them as well as the patient advocacy sessions. 

The Patient Advocates Track Sessions are designed by the ESMO Patient Advocates Working Group (PAWG) and represent an opportunity for all Congress delegates to learn, share and explore areas of collaboration while discussing topical issues for patients and survivors that directly impact cancer care and medical research.

ESMO 2018 - Securing access to optimal cancer care

Patient Advocacy Track – Advanced Programme

Friday, 19 October 2018 

14:30-15:45         Knowledge is power: Educating patients and advocates

Chairs: Jan Geissler, DE and Bettina Ryll, SE

ESMO 2018 Patient Advocacy - Knowledge is power

Patients advocates are not only in contact with many patients but also increasingly involved in healthcare decision making. Knowledge is key to prevent incorrect information from spreading in patient networks and essential for meaningful contributions shaping healthcare. This session looked into successful examples from our community

Welcome to ESMO2018, Bettina Ryll, SE and Josep Tabernero, ES
Reaching patients: The podcast experience, Fredric Johansson, SE
The Myeloma Access Atlas: Training programme, Ananda Plate, BE             
The CML ECABs: Educating for excellence, Jan Geissler, DE

16.00-17.30         Immune therapies going adjuvant: benefits versus risks

Chairs: Bettina Ryll, SE, John Haanen, NL

ESMO 2018 Patient Advocacy - Immune therapies going adjuvant

Immunotherapy checkpoints: what to tell your patients, Bettina Ryll, SE
Benefits of adjuvant therapies, John Haanen, NL
Risks of adjuvant therapies, James Larkin, UK
Discussion: To risk it or not

17.45-19.15         Life after cancer

Chairs: Isabelle Lebrocquy, NL, Tanja Spanic, SL

ESMO 2018 Patient Advocacy - Life after cancer

Every cancer patient wants to survive. However, it takes more than survival to live well. This session investigated the issues cancer survivors face and what we need to tackle to make cancer survival worth living. 

When is a cancer patient cured? Luigino Dal Maso, IT
Big Data Analysis about Socio-economic Consequences of Cancer, Martin Ludwig, NL
The right to be forgotten, Agnes Dumas, FR
Advocating for survivors’ rights, Isabelle Lebrocquy, NL

Saturday 20 October 2018 

12.30-14.00         Pillars of an effective healthcare system in Europe

Chairs: Ananda Plate, BE, Vlad Voiculescu, RO

ESMO 2018 Patient Advocacy - Pillars of an effective healthcare system in Europe

Healthcare is more than a diagnosis or a medicine. This session looked at the different components that make a healthcare system effective, how to measure these, the challenges we face in particular in Central and Eastern Europe and what citizen can do shape the healthcare they desire.

Key components of a well-functioning healthcare system, Wilm Quentin, BE
Special focus on healthcare in CEE, Vlad Voiculescu, RO
Civic participation: how citizens shape the society they live in, Giovanni Moro, IT

18.00-19.30         Cancer prevention

Chairs: Fredrik Johansson, SE, Gilberto Morgan, SE

ESMO 2018 Patient Advocacy App

The best cancer is the one you don’t get. However, effective prevention and early detection are easier said than done and this session explored the need, the potential and the challenges of successful cancer prevention.

Defining non-cancer, Clifton Leaf, USA
Tobacco control: saving lives and driving development, Gilberto Morgan, SE
Behavioral aspects of health-related prevention measures, Arja Leppaenen, SE
Cancer awareness and screening: the challenges, Zorana Maravik, SRB

Sunday, 21 October 2018 

12.30-14.00         The cancer drugs we need: incentivizing innovation in cancer

Chairs: Bettina Ryll, SE, Charlotte Roffiaen, IT

ESMO 2018 Patient Advocacy - The cancer drugs we need

Despite significant progress, cancer remains far from having come a curable disease for all and highlighting the need for novel therapies and therapeutic strategies. How can we incentivize the development of much-needed therapies while ensuring that the end product is accessible to all those in need?

Shaping Policies to drive innovation in cancer, Richard Sullivan, UK
Incentivizing innovation, Jack Scannel, UK
Patient advocate driving innovation, Bettina Ryll, SE 

18.00-19.30         Snake oil sold as science: how to protect patients from pseudoscience

Chairs: Gilliosa Spurrier, FR, Matthias Preusser, AT

ESMO 2018 Patient Advocacy - Snake oil sold as science

Pseudoscience and ‘fake news’ in medicine pose a particular threat to patients. This session helped participants to understand more about the issues, the role of responsible journalism and what patient networks currently do to keep patients safe! 

Pseudoscience and having to destroy false hope: the oncologist’s perspective, Pascal Wolter, BE
Characteristics of pseudoscience, Edzard Ernst, UK
The responsibility of journalism in science reporting, Herny Scowcroft, UK
Preventing pseudoscience on patient forums, Gilliosa Spurrier, FR

Monday, 22 October 2018 

12.30-14.00         The Hans Keulen Memorial Debate: Cancer heroes: do they exist? And who are they?

Chair: Kathy Oliver, UK 

ESMO 2018 Patient Advocacy - The Hans Keulen Memorial Debate

Another edition of this special debate, this year's topic was whether cancer patients should be considered heroes - or not. 

(caregiver) Anita Waldmann, DE, (patient) Martin Inderbitzin, CH
(clinician) Florian Strasser, CH (nurse) Andreas Charalambous, CY
Discussion with the audience and presentation teams

ESMO 2018 Patient Advocacy Track Supporters

The ESMO 2018 Patient Advocacy Track is kindly supported by the following companies:

  • Amgen
  • AstraZeneca
  • BMS
  • Lilly
  • Merck
  • Novartis
  • Pfizer
  • Roche

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings